

Steven J Chadban

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2647262/publications.pdf>

Version: 2024-02-01

69
papers

4,284
citations

257450

24
h-index

114465

63
g-index

70
all docs

70
docs citations

70
times ranked

6853
citing authors

#	ARTICLE	IF	CITATIONS
1	Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2518.	7.4	760
2	TLR4 activation mediates kidney ischemia/reperfusion injury. <i>Journal of Clinical Investigation</i> , 2007, 117, 2847-2859.	8.2	720
3	HMGB1 Contributes to Kidney Ischemia Reperfusion Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1878-1890.	6.1	315
4	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. <i>Transplantation</i> , 2020, 104, S11-S103.	1.0	306
5	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1979-1991.	6.1	193
6	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. <i>Transplantation</i> , 2020, 104, 911-922.	1.0	172
7	Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1267-1281.	6.1	153
8	Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. <i>Annals of Internal Medicine</i> , 2020, 173, 426-435.	3.9	144
9	The Treatment of Antibody-Mediated Rejection in Kidney Transplantation. <i>Transplantation</i> , 2018, 102, 557-568.	1.0	128
10	TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy. <i>PLoS ONE</i> , 2014, 9, e97985.	2.5	111
11	The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F143-F154.	2.7	106
12	Death after Kidney Transplantation: An Analysis by Era and Time Post-Transplant. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2887-2899.	6.1	92
13	The Role of TLR2 and 4-Mediated Inflammatory Pathways in Endothelial Cells Exposed to High Glucose. <i>PLoS ONE</i> , 2014, 9, e108844.	2.5	91
14	Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. <i>Transplantation</i> , 2020, 104, 708-714.	1.0	73
15	Anemia After Kidney Transplantation Is Not Completely Explained by Reduced Kidney Function. <i>American Journal of Kidney Diseases</i> , 2007, 49, 301-309.	1.9	62
16	Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 26-33.	11.4	57
17	KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. <i>Nephrology</i> , 2012, 17, 204-214.	1.6	56
18	Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice. <i>Kidney International</i> , 2014, 85, 824-832.	5.2	56

#	ARTICLE	IF	CITATIONS
19	Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. <i>Transplantation Direct</i> , 2019, 5, e416.	1.6	56
20	Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the TromsÅ, study. <i>Nutrition Journal</i> , 2015, 14, 49.	3.4	47
21	Interleukin 17A promotes diabetic kidney injury. <i>Scientific Reports</i> , 2019, 9, 2264.	3.3	46
22	The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. <i>Kidney International</i> , 2017, 91, 954-963.	5.2	44
23	Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice. <i>Scientific Reports</i> , 2018, 8, 8319.	3.3	40
24	Macrophages and Kidney Transplantation. <i>Seminars in Nephrology</i> , 2010, 30, 278-289.	1.6	31
25	Health-Related Quality of Life in People Across the Spectrum of CKD. <i>Kidney International Reports</i> , 2020, 5, 2264-2274.	0.8	25
26	Suspension and resumption of kidney transplant programmes during the COVID-19 pandemic: perspectives from patients, caregivers and potential living donors – a qualitative study. <i>Transplant International</i> , 2020, 33, 1481-1490.	1.6	21
27	Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 481-95.	0.5	21
28	Pregnancy Outcomes for Kidney Transplant Recipients With Transplantation as a Child. <i>JAMA Pediatrics</i> , 2015, 169, e143626.	6.2	20
29	Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression. <i>BMC Nephrology</i> , 2018, 19, 55.	1.8	20
30	Immunosuppression in renal transplantation: some aspects for the modern era. <i>Transplantation Reviews</i> , 2008, 22, 241-251.	2.9	19
31	One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study). <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1061-1072.	6.1	19
32	Development and outcomes of de novo donor-specific antibodies in low, moderate, and high immunological risk kidney transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 1351-1364.	4.7	19
33	Patient awareness and beliefs about the risk factors and comorbidities associated with chronic kidney disease : A mixed-methods study. <i>Nephrology</i> , 2017, 22, 374-381.	1.6	18
34	Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, S19-S30.	2.6	17
35	Significant impact of COVID-19 on organ donation and transplantation in a low-prevalence country: Australia. <i>Kidney International</i> , 2020, 98, 1616-1618.	5.2	17
36	Evolution of Glycemic Control and Variability After Kidney Transplant. <i>Transplantation</i> , 2018, 102, 1563-1568.	1.0	16

#	ARTICLE	IF	CITATIONS
37	Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation. <i>Trials</i> , 2020, 21, 428.	1.6	16
38	Macrophages in renal transplantation: Roles and therapeutic implications. <i>Cellular Immunology</i> , 2014, 291, 58-64.	3.0	15
39	De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study. <i>American Journal of Transplantation</i> , 2018, 18, 2977-2986.	4.7	15
40	Screening for Asymptomatic Coronary Artery Disease in Waitlisted Kidney Transplant Candidates: A Cost-Utility Analysis. <i>American Journal of Kidney Diseases</i> , 2020, 75, 693-704.	1.9	14
41	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.	2.9	12
42	Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-36 utility and mental component SF-36 quality of life: An AusDiab analysis. <i>Nephrology</i> , 2019, 24, 605-614.	1.6	10
43	Minimal change disease in a patient receiving checkpoint inhibition: Another possible manifestation of kidney autoimmunity?. <i>Cancer Reports</i> , 2020, 3, e1250.	1.4	9
44	Deceased Donor Kidney Transplantation in New Caledonia: A Unique Collaboration With Australia. <i>Transplantation</i> , 2020, 104, 1-3.	1.0	9
45	Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19. <i>Kidney International</i> , 2022, 101, 1077-1080.	5.2	9
46	Global Perspective on Kidney Transplantation: Australia. <i>Kidney360</i> , 2021, 2, 1641-1644.	2.1	8
47	Factors Associated With Advanced Colorectal Neoplasia in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2022, 79, 549-560.	1.9	8
48	Improving Our Understanding of Quality of Life in CKD. <i>American Journal of Kidney Diseases</i> , 2016, 67, 820-821.	1.9	7
49	Young adult onset type 2 diabetes versus type 1 diabetes: Progression to and survival on renal replacement therapy. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 108023.	2.3	7
50	Staged versus concurrent native nephrectomy and renal transplantation in patients with autosomal dominant polycystic kidney disease: A systematic review. <i>Transplantation Reviews</i> , 2022, 36, 100652.	2.9	7
51	Cancer in ESRD: Clear on the Epidemiology, Hazy on the Mechanisms. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1272-1275.	6.1	5
52	High-dose intravenous methotrexate with high-flux, extended-hours haemodialysis in treatment of primary central nervous system, post-transplant lymphoproliferative disorder and end-stage kidney disease: A case report. <i>Nephrology</i> , 2018, 23, 1063-1064.	1.6	5
53	Invasive Management of Coronary Artery Disease in Advanced Renal Disease. <i>Kidney International Reports</i> , 2021, 6, 1513-1524.	0.8	5
54	Is it time to increase access to transplantation for those with diabetic end-stage kidney disease?. <i>Kidney International</i> , 2014, 86, 464-466.	5.2	4

#	ARTICLE	IF	CITATIONS
55	Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials. <i>Transplantation</i> , 2019, 103, 1705-1713.	1.0	4
56	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 665-673.	6.1	4
57	The Utility of Pre- and Post-Transplant Oral Glucose Tolerance Tests: Identifying Kidney Transplant Recipients With or at Risk of New Onset Diabetes After Transplant. <i>Transplant International</i> , 2022, 35, 10078.	1.6	4
58	Preexisting Cancer in Transplant Candidates. <i>Transplantation</i> , 2018, 102, 1037-1038.	1.0	3
59	Rapidly progressive crescentic diabetic nephropathy: two case reports. <i>Internal Medicine Journal</i> , 2022, 52, 479-484.	0.8	3
60	Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2276-2277.	6.1	2
61	Prevalence of chronic kidney disease in obesity hypoventilation syndrome and obstructive sleep apnoea with severe obesity. <i>Sleep Medicine</i> , 2020, 74, 73-77.	1.6	2
62	Comparison of the effect of single vs dual antiplatelet agents on post-operative haemorrhage after renal transplantation: A systematic review and meta-analysis. <i>Transplantation Reviews</i> , 2021, 35, 100594.	2.9	2
63	Statistical analysis plan for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a randomised controlled trial of the effect of intravenous fluid therapy with balanced crystalloid versus saline on the incidence of delayed graft function in deceased donor kidney transplantation. <i>Trials</i> , 2022, 23, 52.	1.6	2
64	Dialysis Disequilibrium: Is Acidosis More Important than Urea?. <i>Case Reports in Nephrology</i> , 2022, 2022, 1-5.	0.4	1
65	Relationship Between Urinary Phosphate and All-Cause and Cardiovascular Mortality in a National Population-Based Longitudinal Cohort Study. , 2021, , .		1
66	Josette Marie Eris April 7, 1959 to April 6, 2016 TTS Councilor and Professor. <i>Transplantation</i> , 2016, 100, 1596.	1.0	0
67	Novel TOF-MS Means of Quantifying ApoAI Amyloid Protein Load After Combined Liver Kidney Transplantation. <i>Transplantation</i> , 2018, 102, e192-e193.	1.0	0
68	MO518INSIDE CKD: MODELLING THE ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE IN THE AMERICAS AND THE ASIA-PACIFIC REGION USING PATIENT-LEVEL MICROSIMULATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
69	The "New Caledonia COVID-19 Paradox": Dramatic Indirect Impact of the Pandemic on Organ Donation and Transplantation in a Nonprevalence Country. <i>Kidney International Reports</i> , 2021, 6, 2519-2520.	0.8	0